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 46 
Abstract 47 
Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single nucleotide 48 
polymorphisms (SNPs) on subgroups of patients undergoing allogeneic haematopoietic stem 49 
cell transplantation (HSCT) revealed an association with transplant outcome. This study 50 
further evaluated the association of non-HLA polymorphisms with overall survival in a cohort 51 
of 762 HSCT patients using data on 26 polymorphisms in 16 non-HLA genes. When viewed in 52 
addition to an already established clinical risk score (EBMT-score), three polymorphisms: 53 
rs8177374 in the gene for MyD88-adapter-like (MAL) (p=0.026), rs9340799 in the estrogen 54 
receptor gene (ESR) (p=0.003) and rs1800795 in interleukin 6 (IL-6) (p=0.007) were found to 55 
be associated with reduced overall survival, while the haplo-genotype (ACC/ACC) in 56 
interleukin 10 (IL-10) was protective (p=0.02). The addition of these non-HLA polymorphisms 57 
in a Cox regression model alongside the EBMT-score improved discrimination between risk 58 
groups and increased the level of prediction compared to the EBMT-score alone (gain in 59 
prediction capability for EBMT-genetic-score 10.8%). Results also demonstrated how 60 
changes in clinical practice through time have altered the effects of non-HLA analysis. 61 
The study illustrates the significance of non-HLA genotyping prior to HSCT and the 62 
importance of further investigation into non-HLA gene polymorphisms in risk prediction.  63 
  64 
 65 
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4 
Introduction 67 
Haematopoietic stem cell transplantation (HSCT) is the major curative therapy for disorders 68 
of the blood and immune system. However, the rate of survival in patients with HSCT has 69 
remained at 40-60% for the last two decades, owing to post-transplant complications 70 
including infection, graft-versus-host disease (GvHD), and relapse. 71 
Five relevant clinical factors influencing transplantation success in patients with 72 
haematological disorders, including chronic myeloid leukaemia (CML) and acute lymphocytic 73 
and acute myeloid leukaemia (ALL and AML), have been identified by the European Group 74 
for Blood and Marrow Transplantation (EBMT). These risk factors (EBMT-factors) are patient 75 
age, sibling donor/matched unrelated donor (MUD), patient-donor gender combination, 76 
stage of disease, and time from diagnosis to transplant. A clinical risk score (EMBT-score) 77 
utilising the EBMT-factors was proposed in order to aid the prediction and prevention of 78 
post-transplant complications.1-4 79 
Previous genetic association studies have suggested that, besides HLA genes, non-HLA genes 80 
may play an important role in transplant outcome. To date, these studies with single 81 
nucleotide polymorphisms (SNPs) have used small subsets of patients.5-9 Although genome-82 
wide association studies (GWAS) have been performed,10 no SNP genotypes have been 83 
clearly identified so far that could be used to predict outcome. 84 
In this study, we assessed the association of candidate polymorphisms with overall survival 85 
using a large cohort of patients undergoing HSCT. The goal was to identify non-HLA SNPs 86 
with an impact on overall survival when viewed in addition to the already established EBMT-87 
score. Prediction capability was also evaluated. Since changes in transplant protocols can 88 
affect transplant outcome, the study also took into account date of transplant. 89 
 90 
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Methods 91 
Patients 92 
A total of 762 patients with malignant haematological diseases, having complete data on the 93 
EBMT-factors1,3,4 and with known date of death or last contact, were included in the study. 94 
These patients were transplanted between November 1983 and December 2005 at seven 95 
European transplant centres. The patients and donors gave informed consent to participate 96 
in the study in accordance with the Declaration of Helsinki and EBMT guidelines. The 97 
protocol was approved by the Local Research Ethics Committee at the coordinating centre 98 
(Newcastle upon Tyne, UK). Follow-up time was between 7 months and 20 years, with a 99 
median of 5-6 years. Patient and donor characteristics are presented in Table 1. Overall, 100 
death occurred in 399 patients (52%). Causes of death were relapse (41%), GvHD (18%), 101 
infection (18%), multiple organ failure (5%), acute respiratory distress syndrome (4%), veno-102 
occlusive disease (2%), interstitial pneumonitis (1%), and others (11%). The majority of the 103 
cohort after the year 2000 had high-resolution tissue typing for HLA Class I A,B,C, and Class II 104 
DP,DQ, and DR.  105 
  106 
Candidate non-HLA Polymorphisms  107 
DNA was prepared from archived frozen peripheral blood mononuclear cells. Genotyping 108 
was outsourced to Kbioscience (http://www.kbioscience.co.uk) who used fluorescence-109 
based competitive PCR technology (KASPar) and designed the assays for the SNPs based on 110 
the DNA sequence (50 bases) either side of the SNP. Genotypes were available for 743 111 
patient-donor pairs on the following genes: CD14, CD91, C3, ESR1, GCR, HSP70-hom, IFNG, 112 
IL1RN, IL4, IL6, IL10, IL12B, IL13, LOX1, MAL, MDR1, NOD2, TNF, TNFRSF1B, and VDR (Table 113 
2). Candidate SNPs were selected according to findings on smaller patient cohorts by our 114 
6 
coordinating centre in Newcastle (ESR1,11 IFNG,12 IL1RN,13 IL4,14 IL6,15,16 IL10,17 IL13,18 TNF,19 115 
TNFRSF1B,20 and VDR21). SNPs were also selected according to findings by other groups in 116 
HSCT (MAL,22 MDR1,23,24,25 and NOD226), and according to previous disease association 117 
studies in autoimmune (CD14,27 GCR,28,29 HSP70-hom,30 and IL12B31) or inflammatory 118 
disease (and recently found to be de-regulated in a rat model for GvHD:32 C3,33 LOX1,34 and 119 
CD9135). 120 
 121 
Statistical analysis 122 
Clinical differences in patients treated up to and after year 2000 were assessed using Fisher’s 123 
exact test. This division in time was chosen as transplant protocols were changed at that 124 
time with the introduction of Imatinib and a subsequent increase in survival rate.2 125 
Biallelic SNPs were considered under the additive, dominant, and recessive modes of 126 
inheritance10 (Supplementary Section A). In the models, each SNP was used with the mode 127 
demonstrating the strongest association with survival. 128 
The genes HSP70-hom, IL12B, and MDR1 and GCR-haplotype were excluded from the 129 
analysis due to missing genotypes (missingness>33%). A total of 26 polymorphisms from 16 130 
genes were available for analysis (Table 2).  131 
A power of 80% in the cohort with 52% deaths was achieved for SNPs in an additive mode 132 
for sample sizes n≥300, minor allele frequency (MAF)>15%, and an expected hazard ratio 133 
HR≥1.50. In a dominant mode, this power was achieved for n≥400. In a recessive mode, this 134 
was attained for n≥500, MAF≥25%, and HR≥2.00. A few SNPs with a MAF<10% (i.e. IL6 135 
rs1800796, LOX1 rs11053646, and the three SNPs in NOD2) had a very low power at all 136 
settings; even so, we retained these SNPs for further analysis. 137 
 138 
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Association of risk score for overall survival 139 
The EBMT risk score (EBMT-score) was derived by a summation procedure of the EBMT-140 
factors.1,3,4 The EBMT-score was subsequently implemented in analyses on an ordinal scale 141 
[low to high risk 0-7]. The additional effect of each individual polymorphism was evaluated 142 
using separate Cox regression models. The likelihood ratio test (LRT) was applied to compare 143 
a Cox regression model including the EBMT-score and one polymorphism to a model 144 
including only the EBMT-score; a nominal p-value of 0.05 was used. Analyses were 145 
performed for the cohort as a whole as well as for several subgroups.  146 
Using stepwise selection, we built an additional Cox regression model to establish whether 147 
multiple non-HLA polymorphisms improved the model when added in with the EBMT-score 148 
(α=0.05 for variable entry and α=0.10 for variable removal36). All available polymorphisms 149 
were chosen as candidates in this procedure. Hazard ratios (HRs) and 95% confidence 150 
intervals (95% CI) were reported. 151 
A new risk score (EBMT-genetic-score) was developed using this last Cox regression model. 152 
The score was derived by summing up the clinical EBMT-score and the genetic score points 153 
given for the polymorphisms. The latter were obtained by dividing the respective regression 154 
coefficients by the coefficient of the EBMT-score and rounding to the nearest integer37 155 
(Supplementary Section B). 156 
 157 
Assessment of prediction 158 
Two statistical approaches were used to assess the risk score prediction capability: the 159 
concordance index (C-index)3,4,38-40 and the R-square measure of the gain in prediction (R2).41 160 
The C-index measures the agreement between risk score and observed survival time. A 161 
higher risk score should correspond to a shorter observed survival time. A C-index=0.5 162 
8 
implies that a risk score has no predictive discrimination, whereas C-index=1 implies 163 
maximum predictive discrimination. The U-statistic40 was also used to test whether the 164 
EBMT-genetic-score was better than the EBMT-score as regards agreement with observed 165 
survival time. In addition, R2 was used to quantify the improvement in prediction41 of the 166 
new EBMT-genetic-score over the EBMT-score. This measure is a combination of the 0.632 167 
bootstrap estimate of prediction error42 and the explained variation using Schoenfeld 168 
residuals43-44 (see Supplementary Section C). Larger values of R2 (>0%) mean that the EBMT-169 
genetic-score correctly predicts outcome more often than the EBMT-score. R2=0% means 170 
that both scores have equivalent predictive ability and R2=100% means that the EBMT-171 
genetic-score has perfect predictive ability (i.e. the predicted and the actual outcomes 172 
always agree). 173 
 174 
Results 175 
Clinical characteristics 176 
Sixty percent of the patients underwent HSCT after the year 2000. There was evidence that, 177 
after 2000, transplants involved more patients and donors over 40 years of age, more HLA-178 
matched unrelated donors, more lymphoma, more donor cells from peripheral blood, more 179 
later stage disease, more T-cell depletion, and more reduced-intensity conditioning (RIC) 180 
(Table 1). 181 
There was no significant centre effect on overall survival (likelihood ratio test, P value= 0.49). 182 
 183 
Association of the EBMT risk score and single polymorphisms with overall survival  184 
The EBMT-score1,3,4 was significantly associated with overall survival (HR=1.16, 95% CI=1.09-185 
1.24, p<0.001). 186 
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The top ten candidate polymorphisms associated with overall survival in the whole cohort, 187 
while controlling for EBMT-score, are given in Table 3. The IL10 haplotype in donors 188 
demonstrated the lowest p-value and the presence of ACC/ACC was protective (HR=0.48, 189 
95% CI=0.29-0.80, LRT p-value=0.002). This haplotype was also the only polymorphism 190 
significantly associated with survival in all subgroups (Supplementary Table 1). Nine of the 191 
ten polymorphisms were also highest ranked amongst patients without T-cell depletion and 192 
with myeloablative conditioning regimens. IL10 haplotype, IL10 rs1800896(G), IL4 193 
rs2243250(T), and IL6 rs1800797(A) in donors, ESR1 rs2234693(C) and GCR rs33388(T) in 194 
patients were observed in over 50% of the assessed clinical subgroups. 195 
 196 
Association and prediction of multiple polymorphisms with overall survival  197 
After stepwise selection, the final model contained the EBMT-score and four selected 198 
polymorphisms (n=419 due to missing genotypes). The presence of haplo-genotype ACC/ACC 199 
of IL10 in donors was protective against patient death (HR=0.49, 95% CI=0.26-0.89, p-200 
value=0.020). The risk of death increased with an increased number of T alleles in MAL 201 
rs8177374 in patients (additive, HR=1.34, 95% CI=1.04-1.74, p-value=0.026), with the 202 
presence of allele G in ESR1 rs9340799 in patients (dominant, HR=1.52, 95% CI=1.15-2.01, p-203 
value=0.003), and with the increased number of C alleles in IL6 rs1800795 in donors 204 
(additive, HR=1.29, 95% CI=1.07-1.55, p-value=0.007) (Table 4, Supplementary Figure 1).  205 
Three out of four of these polymorphisms were significantly associated with death due to 206 
relapse. In addition, MAL rs8177374 was associated with death due to GvHD and IL6 207 
rs1800795 was associated with death due to infection (Supplementary Table 2). 208 
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When the multivariate Cox regression model (Table 4) was compared to a model containing 209 
the EBMT-score alone, the estimated R2 for gain in prediction indicated a 5.1% gain in 210 
prediction ability by adding the four polymorphisms (separately) to the EBMT-score. 211 
 212 
Comparing EBMT-genetic-score and EBMT-score 213 
The new EBMT-genetic-score, derived through summing the individual risk score values 214 
(Supplementary Section B), ranged from 1 to 15. The scores were grouped into five distinct 215 
categories according to the observed groupings of the Kaplan-Meier survival curves (results 216 
not shown). The Cox regression model, with five ordered categories of the EBMT-genetic-217 
score, revealed increasing hazard ratios with increasing EBMT-genetic-score (n=419, Table 218 
5). The risk values of the EBMT-genetic-score displayed a clearer separation of the survival 219 
curves when compared to values of the EBMT-score (Supplementary Figure 2). 220 
Kaplan-Meier curves for the EBMT-genetic-score were plotted to establish if the EBMT-221 
genetic score is appropriate for the clinical subgroups: disease diagnosis, sibling 222 
donor/matched unrelated donor, T-cell depletion, conditioning regimen, and year of 223 
transplantation. The plots consistently demonstrated that higher risk scores corresponded to 224 
lower survival (Supplementary Figure 3). 225 
For the whole cohort, the higher EBMT-genetic-score corresponded to shorter observed 226 
survival times compared to the EBMT-score (U-statistic p-value<0.001, Table 6). This also 227 
proved to be the case in subgroups of patients transplanted before and after 2000. 228 
Estimation of the gain in prediction ability indicated that there was benefit in utilising the 229 
single EBMT-genetic-score (R2=10.8%, Table 6) over the previous model containing the 230 
EBMT-score and four separate polymorphisms (R2=5.1%). 231 
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Kaplan Meier survival curves for EBMT-score and EBMT-genetic-score before and after 2000 232 
(n=419) appear in Figures 1a-1d. Compared to the EBMT-score, the EBMT-genetic-score 233 
better discriminates the survival curves and a higher score consistently corresponds to a 234 
lower survival probability. It was also apparent that, when using the EBMT-genetic-score, 235 
those treated after 2000 had improved chances of survival in comparison with those treated 236 
before 2000 (Figures 1c, 1d). For those with the lowest scores (1-6), 3-year survival was 85% 237 
and 95% for patients treated before and after 2000, respectively; for those with the highest 238 
scores (13-15), 1-year survival was 15% and 42% for patients treated before and after 2000, 239 
respectively. 240 
 241 
Discussion 242 
The aim of this work was to study the effect of non-HLA polymorphisms on overall survival of 243 
HSCT patients in addition to the EBMT-score. In our study, the IL10 promoter haplo-244 
genotype ACC/ACC in donors was one of the most important polymorphisms associated with 245 
improved overall survival. IL10 is an important cytokine in the regulation of the immune 246 
response. However, it can have a stimulatory effect on B cells, increasing MHC class II 247 
expression and antibody production. IL10 haplotypes have been shown to correlate with 248 
IL10 protein production,45 with the GCC haplotype being associated with the highest IL10 249 
production. 250 
The ATA/ACC genotype has been identified as a protective factor for overall survival in CML 251 
patients with sibling donors.9 SNP rs1800872(A) and haplotype ACC in patients have been 252 
shown to demonstrate a strong association with severe acute GvHD (aGvHD III-IV) in patients 253 
with matched related donors.7,10 In our whole cohort, the IL10 promoter haplo-genotype 254 
ACC/ACC in donors proved to be significantly associated with increased overall survival, 255 
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whereas SNP rs1800872(A) in patients revealed only borderline association. The ACC/ACC 256 
genotype in the donor is associated with intermediate production of IL10 and the ACC 257 
haplotype has been shown to be protective in aspergillosis.46 The AA genotype of IL10 258 
rs1800872 in the patient is associated with a decreased risk of aGvHD47 and an increased risk 259 
of non-relapse mortality; this was confirmed in follow-up GWAS studies.10,48 In addition, the 260 
presence of the GG genotype of IL10 rs1800896 in the patient was found to be associated 261 
with the risk of chronic GvHD (cGvHD).49 262 
Furthermore, we discovered that MAL rs8177374(T) in patients is associated with reduced 263 
overall survival whereas parallel smaller studies have reported that the presence of the T 264 
allele in donors resulted in less cGvHD and a reduction in transplant-related mortality. In 265 
addition, the presence of the T allele in patients was associated with an increased risk of 266 
relapse.50 Our study revealed a strong association between the presence of the T allele and 267 
relapse and an increased risk of death in patients who relapsed. Moreover, the T allele was 268 
strongly associated with GvHD. The T allele is regarded in the literature as the inflammatory 269 
allele, and T-heterozygous individuals have increased protection from infection. 270 
Interestingly, another study revealed that patients transplanted from donors with the T 271 
allele have a lower incidence of fungal infections, aGvHD, and improved overall survival.22 272 
MAL protein was originally identified in intermediate and late stages of T-lymphocyte 273 
differentiation51 and the MAL mRNA expression was also found to be related with 274 
differentiation in urothelial cells, neuronal cells,52,53 and oesophageal epithelium.54 The MAL-275 
A variant containing all four exons is abundantly expressed in peripheral blood 276 
lymphocytes55 and positively expressed in the gastrointestinal tract, respiratory tract, and 277 
haematopoietic system. MAL is important in the innate immune response; it is involved in 278 
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Toll-like receptor signalling,56 so could be important in the development of aGVHD in the 279 
recipient. 280 
Our study also indicated that ESR1 rs9340799(G) in patients is associated with reduced 281 
overall survival. The G allele has been previously reported as associated with reduced overall 282 
survival and increased risk of aGvHD in patients with HLA-matched siblings.11 ESR1 is thought 283 
to inhibit IL6 production.57 284 
Furthermore, we found IL6 rs1800795(C) in donors to be associated with reduced overall 285 
survival. The G allele in patients and/or donors has been reported by GWAS studies as a risk 286 
factor for both aGvHD and cGvHD in patients with HLA-matched related10,21 and unrelated10 287 
donors. In our study, there was evidence of an increased risk of aGvHD in patients 288 
transplanted from donors with the C allele present. Among these patients, those 289 
transplanted before 2000 had evidence of reduced survival compared to those transplanted 290 
later (Supplementary Figure 4a), possibly as a result of a higher rate of standard 291 
myeloablative conditioning before 2000. 292 
The G allele of this SNP is reported to correlate with higher serum IL6 levels in systemic-293 
onset juvenile chronic arthritis.58 However, the CC genotype has been associated with higher 294 
levels of IL6 in polymyalgia rheumatica.59 It could therefore be that increased levels of IL6 in 295 
our cohort exacerbated the inflammatory milieu, leading to increased transplant-related 296 
complications such as infection and poorer survival. 297 
We have also demonstrated that polymorphisms modelled via Cox regression, either in a 298 
joint model with the EBMT-score or combined with the latter as a single EBMT-genetic-score 299 
factor, contribute to a better discrimination of the risk groups (C-index) and increase the 300 
prediction of survival (R2) compared to the EBMT-score alone. Changes in HSCT clinical 301 
protocols during 2000 greatly improved patient survival. The consideration of an EBMT-302 
14 
genetic-score highlighted an improvement in survival, especially for those at higher risk of 303 
death. More transplants from MUDs were performed after 2000 and it could be argued that 304 
the improvement in survival of patients with high-risk non-HLA genotypes is due to the 305 
improved quality of HLA matching after 2000. However, no difference in survival was evident 306 
between siblings or MUD patients transplanted after 2000 (Supplementary Figure 4b). 307 
In addition, a recent review has revealed that other pre-transplant clinical factors (e.g., CMV 308 
status and Karnofsky performance score) also play a role in survival and could be used 309 
alongside EBMT-score4.  310 
In conclusion, we hypothesise that implementing risk scores for pre-transplant risk 311 
assessment from clinical and genetic factors enhances the prediction of overall survival for 312 
patients undergoing HSCT. The potential of considering non-HLA polymorphisms in pre-313 
transplant risk assessment is evident with the promising results for polymorphisms in genes 314 
IL10, MAL, ESR1 and IL6. Further investigations into pre-transplant risk assessment could 315 
also include other potential predictors such as mRNA and microRNA expression.60  316 
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Figure 1 Kaplan-Meier curves of patients undergoing HSCT up to and after the year 2000 518 
(n=419) for 5 years follow-up a) EBMT-scores before 2000, b) EBMT-scores after 2000, c) 519 
EBMT-genetic-scores before 2000 and d) EBMT-genetic-scores after 2000. 520 
 521 
Supplementary Figure 1 Kaplan-Meier survival curves (for 5years follow-up) of patients 522 
undergoing HSCT for each polymorphism appearing in the Cox regression model (n=419) a) 523 
IL10 haplotype – donor b) MAL rs8177374– patient c) ESR1 rs9340799 - patient d) IL6 524 
rs1800795-donor. 525 
 526 
Supplementary Figure 2 Kaplan-Meier survival curves (for 5 years follow-up) of patients 527 
undergoing HSCT a) EBMT-score (n=743), b) EBMT-genetic-score (n=419). 528 
 529 
Supplementary Figure 3 Kaplan-Meier survival curves (for 5 years follow-up) of patients 530 
undergoing HSCT according to the EBMT-genetic-score, by various clinical subgroups.  531 
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Supplementary Figure 4 Kaplan-Meier survival curves (for 5 years follow-up) of patients 533 
undergoing HSCT according to year of transplant, by type of donor 534 
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Supplementary Table 1 Top ten polymorphisms from the whole cohort that remained as top 536 
polymorphisms in the subgroup analyses for association with overall survival. 537 
 538 
Supplementary Table 2 P-values for the association of selected polymorphisms with 539 
different causes of death (n=419), using a Cox regression model including a single 540 
polymorphism and the EBMT-score. 541 
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Supplementary Sections A, B, C – Additional information describing: a) the method of coding 542 
the biallelic SNPs (additive, dominant and recessive), b) an example of risk score calculation 543 
c) derivation of the R-square measure of the gain in prediction. 544 
Table 1. Clinical characteristics of patients and donors prior to HSCT (n=762) 
    Year of Transplant 
Factors Categories No.         (%)  ≤ 2000 >2000 
    No.     (%) No.     (%) 
No. of patient/donor   762   302  460  
         
Age of patient at 
transplantation 
(years)a,b 
<20 years 32 (4)  22 (7) 10 (2) 
20-40 years 346 (46)  171 (57) 175 (38) 
>40 years 384 (50)  109 (36) 275 (60) 
         
Age of donor (years)b,g <20 years 34 (4)  25 (8) 9 (2) 
 20-40 years 424 (56)  169 (56) 255 (55) 
 >40 years 286 (38)  98 (33) 188 (41) 
 NAc 18 (2)  10 (3) 8 (2) 
         
Patient/donor gender 
combinationa 
Male/female 164 (22)  64 (21) 100 (22) 
Other 598 (78)  238 (79) 360 (78) 
         
Type of donora,b Sibling 395 (52)  188 (62) 207 (45) 
 HLA-matched unrelated(MUD) 367 (48)  114 (38) 253 (55) 
         
Haematological 
diseaseb,g 
Acute leukaemia (AL)  391 (51)  154 (51) 237 (52) 
Chronic myeloid leukaemia (CML) 172 (23)  108 (36) 64 (14) 
Lymphoma 112 (15)  28 (9) 84 (18) 
 other diagnosesd 87 (11)  12 (4) 75 (16) 
         
Source of stem cellsb Bone Marrow 356 (47)  247 (82) 109 (24) 
 Peripheral blood 388 (51)  48 (16) 340 (74) 
 Both sources 3 (0)  2 (<1) 1 (<1) 
 NAc 15 (2)  5 (2) 10 (2) 
         
Patient/donor CMV 
statusg 
Negative/Negative 227 (30)  88 (29) 139 (30) 
Other 511 (67)  201 (67) 310 (67) 
 NAc 24 (3)  13 (4) 11 (3) 
         
Stage of disease at 
transplantationa,b,g 
Early 328 (43)  166 (55) 162 (35) 
Intermediate 196 (26)  63 (21) 133 (29) 
 Late 238 (31)  73 (24) 165 (36) 
         
Time from diagnosis to 
transplanta 
≤12 months 439 (58)  175 (58) 264 (57) 
>12 months 323 (42)  127 (42) 196 (43) 
         
T-cell depletionb T-cell depletion  263 (35)  68 (23) 195 (42) 
 No T-cell depletion 499 (65)  234 (77) 265 (58) 
         
Conditioning regimenb 
 
Standard myeloablative 503 (66)  263 (87) 240 (52) 
Reduced-Intensity (RIC) 259 (34)  39 (13) 220 (48) 
         
Transplantation centerb Vienna/Prague e 225 (30)  73 (24) 152 (33) 
 Regensburg/Munich f 217 (28)  72 (24) 145 (31) 
 Newcastle 204 (27)  123 (41) 81 (18) 
 Rostock 73 (9)  23 (8) 50 (11) 
 Paris 43 (6)  11 (3) 32 (7) 
 a  Clinical EBMT factor3.  
 b  P value ≤ 0.05, Fisher-exact-test for differences between patients treated up to and after 2000. c NA=not available. 
 d  Other diagnoses included: plasma cell neoplasia, myelodysplasia syndrome, and chronic myelomonocytic leukaemia. 
e,f  The centers of Vienna (29% patients) and Prague (1% patients) worked in close collaboration with each other. Hence, 
both centers used similar treatment procedures. Likewise, there were collaborations between the centers of 
Regensburg (27.5% patients) and Munich (0.5% patients). 
 g  Factor showing significant association with overall survival (log-rank test, P value ≤ 0.05). 
 
Table 2. Descriptives of non-HLA SNPs, and other polymorphismsg. (n=743) 
 
Gene name Chr.a 
  SNP 
rs number 
Allele 
pair 
MAb 
MAF % c   Sample Size d  
  patient donor   patient donor   
Cluster determinant 14 (CD14) 5 
 
rs2569190 G/A A 49 47  536 542 
 
Cluster determinant 91 (CD91) 12 
 
rs1799986 C/T T 15 16  514 560 
 
Complement component 3 (C3) 19 
 
rs2230199 C/G G 22 22  523 550 
 
Estrogen receptor 1  (ESR1) 6 
 
rs2234693 C/T C 46 44  646 635 
  
  
rs9340799 G/A G 40 37  646 644 
 
Glucocorticoid receptor  (GCR) 5 
 
rs33389 C/T T 14 15  521 561 
  
  
rs33388 T/A T 44 46  527 562 
  
  
rs6198 G/A G 17 17  533 561 
 Heat shock  (HSP70-hom) e 6 
 
rs2075800 G/A A 35 32  433 417 
 protein 70 Hom 
  
rs2227956 T/C C 18 19  495 488 
 IL1 receptor antagonist  (IL1RN) 2 
 
rs419598 T/C C 24 24  663 671 
 Interleukin 4 Hom (IL4) 5 
 
rs2243250 T/C T 15 16  617 618 
 Interleukin 6 (IL6) 7 
 
rs1800797 G/A A 39 39  561 593 
  
  
rs1800796 C/G C 7 6  582 618 
  
  
rs1800795 G/C C 42 39  664 678 
 
Interleukin 10  (IL10) 1 
 
rs1800896 G/A G 47 46  609 619 
  
  
rs1800872 A/C A 24 26  620 626 
 
Interleukin 12B  (IL12B) e 5 
 
rs3212227 A/C C 21 20  440 471 
 
Interleukin 13  (IL13) 5 
 
rs1800925 C/T T 19 18  543 592 
  
  
rs20541 A/G A 21 22  577 596 
  
  
rs1881457 C/A C 19 19  584 613 
 Oxidized Low-Density (LOX1)  12 
 
rs11053646 G/C G 6 8  517 579 
 Lipoprotein Receptor 1          
MyD88-adapter-like (MAL) 11 
 
rs8177374 T/C T 15 17  507 550 
 
Multi drug resistance (MDR1) e 7 
 
rs1045642 C/T C 47 46  460 485 
 Nucleotide-binding (NOD2) 
oligomerization domain 
containing 2  
16 
 
rs2066844 C/T T 5 5  592 595 
 
  
rs2066845 C/G G 2 1  592 595 
 
  
rs2066847 -/ C C 3 3  592 595 
 
Tumour necrosis factor  (TNF) 6 
 
rs1800629 G/A A 15 15  592 587 
 Tumour necrosis factor  (TNFRSF1B) 
receptor 2 1 
 
rs1061622 T/G G 24 23  618 637 
 
Vitamin D receptor  (VDR) 12 
 
rs731236 T/C C 36 40  630 659 
  
   
rs7975232 C/A   C f 49 47  649 676 
 a Chromosome number. b Minor allele. c Minor allele frequency.  d Available sample size for patient’s or donor’s SNP. 
e Excluded from the statistical analysis because of high percentage of missing genotypes. 
f Minor allele differs between patients (allele A) and donors (allele C). 
g Other non-HLA polymorphisms were from genes: IFNG h, MDR1(three allelic)e, GCR(haplotype)e and IL10(haplotype)i 
h Microsatellite in gene IFNG, located in chromosome 12. Alleles in patients were: 1 (<1%), 2 (47%), 3 (46%), 4 (4%), 5 (2%), 
6 (<1%); the frequencies were similar in donors. 
i Haplotype IL10 from SNPs above: rs1800896, rs1800871 (not genotyped due to complete linkage disequilibrium with the 
other two SNPs), and rs1800872. Haplotypes in patients/donors were: ACC (30%/28%), ATA (23%/25%), GCC (46%/46%), 
G_A (<1%/<1%). 
Table 3. Cox regression estimates for the top ten polymorphisms associated with overall 
survival, in addition to the EBMT-score, ordered according to p-value for the LRT c. 
 
Genes from 
Patient (P-), 
Donor (D-) 
Polymorphism a Hazard 
ratio b 
Confidence 
Interval (95%) b 
LRT  
P value c 
R2 d MAF % e 
 D-IL10 genotype(ACC/ACC) 0.48 0.29  - 0.80 0.002 0.025 28 
 P-MAL rs8177374(T) add. 1.33 1.05  - 1.68 0.021 0.010 15 
 D-IL6 rs1800795(C) add. 1.19 1.03  - 1.38 0.021 0.007 39 
 P-ESR1 rs2234693(C) dom. 1.31 1.03  - 1.67 0.027 0.014 46 
 D-IL13 rs1800925(T) rec. 0.46 0.20  - 1.03 0.032 0.033 18 
 P-GCR rs33388(T) add. 0.83 0.70  - 0.99 0.035 0.003 44 
 D-IL4 rs2243250(T) rec. 0.49 0.22  - 1.10 0.052 0.000 16 
 D-IL6 rs1800797(A) add. 1.18 1.00  - 1.39 0.056 0.001 39 
 P-IL10  rs1800872(A) rec. 0.63 0.38  - 1.05 0.057 0.010 24 
 D-IL10 rs1800896(G) add. 1.16 0.99  - 1.35 0.063 0.000 46 
 
a Polymorphisms were ordered from lowest to highest p value for likelihood ratio test (LRT). SNP rs numbers are followed 
by the minor allele and the respective genetic model: additive (add.), dominant (dom.), or recessive (rec.). 
b Hazard ratio for the polymorphism and  associated 95% confidence intervals were based on the multiple Cox model 
including the EBMT-score and the polymorphism. 
c P value for the likelihood ratio test comparing a multiple model including the EBMT-score and the polymorphism with 
respect to a model including  only the EBMT-score. In bold are p-value≤0.05. 
d R2: Estimated gain in prediction of model containing EBMT-score and the polymorphism vs model containing  EBMT-score 
alone. 
e Minor allele or haplotype frequency of the respective polymorphism tested for association with overall survival. 
Table 4. Cox regression model with multiple polymorphisms and EBMT-score for overall 
survival (n=419) 
 
Factors a  Hazard 
ratio 
Confidence  
interval (95%) 
p-value Reg. 
Coef. b  
Scaled 
Coef. c 
Risk score value d 
EBMT-score 1.22 1.12  - 1.33 <0.001  0.20 1 EBMT-score: 0-7 e 
D-IL10 genotype(ACC/ACC) 0.49f 0.26  - 0.89   0.020 -0.72 4 ACC/ACC:0, others:4 
P-MAL rs8177374(T) add. 1.34f 1.04  - 1.74   0.026  0.29 1 CC:0, CT:1, TT:2 
P-ESR1 rs9340799(G) dom. 1.52f 1.15  - 2.01   0.003  0.42 2 AA:0, (AG or GG):2 
D-IL6 rs1800795(C) add. 1.29f 1.07  - 1.55   0.007  0.25 1 GG:0, GC:1, CC:2 
               
a Patients (P-) or Donors (D-). For the SNPs listed, the rs number is followed by the minor allele and the respective genetic 
model: additive (add.), dominant (dom.), or recessive (rec.). 
b Regression coefficients from the Cox model, equivalent to the log of the hazard ratio. 
c Scaled coefficient was obtained by dividing the regression coefficients by that of the EBMT-score and rounding to the 
nearest integer. 
d Risk score values for polymorphisms contributing to the EBMT-genetic-score was derived using the scaled coefficients. 
(Supplementary Section B) 
e Range of score values for EBMT-score3. 
f Note the effect size, either protective or at risk, is larger than that of EBMT-score. 
 
Table 5. Cox regression model of overall survival with the EBMT-genetic-score using five 
categories (n=419) and its correlation with the EBMT-score. 
 
Cox regression model   Correlation as number of patients with both risk scores 
EBMT-genetic-
score a 
Hazard 
ratio 
Confidence   
Interval (95%) 
p-value   EBMT-genetic-
score 
EBMT-score 
  [0-1] 2 3 4 5 6 7 Total  
1 –6b 1.00  -    -        -   1 –6a 19 13 2 4 2 0 0 40  
7 – 9 2.46 1.23 - 4.93   0.011   7 – 9 29 40 46 24 9 2 0 150  
10 3.62 1.77 - 7.42 <0.001   10 1 11 23 29 9 5 0 78  
11 – 12 4.67 2.33 - 9.33 <0.001   11 – 12 0 3 14 45 34 14 4 114  
13 – 15 7.57 3.58 - 16.00 <0.001   13 – 15 0 0 0 4 10 21 2 37  
  Number 
of 
patients
fdgfgfdg
fg  
                 a EBMT-genetic-score is the sum of the score values of the EBMT-score and of the score values of the four polymorphisms 
(Supplementary Section B). 
b Reference group. 
 
 
Table 6. Prediction of overall survival based on the EBMT-score and the EBMT-genetic-score, 
(n=419) 
 
 
Cohort 
 
n 
 C-Index a Concordance 
EBMT-genetic-score 
vs EBMT-score 
P-value b 
 R2 c 
 EBMT-
score 
EBMT-genetic-
score 
 EBMT-genetic-score 
vs EBMT-score 
Whole cohort 419  0.590 0.630 <0.001  10.8%d 
Up to 2000 173  0.597 0.646 0.0008  1.3%e 
After  2000 
 
246  0.586 0.616 0.0066  25.2%e 
 
a Concordance Index 
b P-value of U-Statistic40 testing for the fraction of pairs for which EBMT-genetic-score is more in agreement with survival 
than the EBMT-score. 
c Gain in prediction for overall survival41. 
d Gain in prediction for overall survival utilising 0.632 estimator that involves a bootstrap procedure. 
e Gain in prediction for overall survival when whole cohort is used as a training set – utilising sub-cohort up to or after 2000 
as a validation set. 
 
 
 
Supplementary Table 1.  
 
Top ten polymorphisms from the whole cohort that remained as top polymorphisms in the 
subgroup analyses for association with overall survival.  
 
Genes from 
 
Patient (P-), 
Donor (D-) 
Polymorphism b 
P value levela in subgroups 
MUD SIB 
T- 
depl 
No T-
depl 
RIC MC AL CML Lymph 
Other 
Dx 
≤2000 >2000 
 Sample size 358 385 256 487 259 484 377 169 110 87 296 447 
 D-IL10 c genotype(ACC/ACC) 3 1 3 1 1 1 2 2 1 1 1 1 
 P-MAL rs8177374(T) - 1 - 1 1 - 1 - - - 1 - 
 D-IL6  rs1800795(C) 1 - - 1 - 1 - 1 - - 1 - 
 P-ESR1  rs2234693(C) - 1 - 1 - 1 - 2 1 - 2 - 
 D-IL13  rs1800925(T) 3 - - 1 - 1 1 - - - - 2 
 P-GCR  rs33388(T) 1 - - - - 1 1 3 - - 2 3 
 D-IL4  rs2243250(T) - 2 - 2 - 1 2 - 2 2 - - 
 D-IL6  rs1800797(A) 1 - - 2 - 2 - 1 - 1 1 - 
 P-IL10  rs1800872(A) - 3 - 1 3 1 - - - 2 - - 
 D-IL10  rs1800896(G) 3 - - 2 2 2 2 - 1 - - 1 
 
MUD: matched unrelated donors, SIB: sibling donors, T-depl: T-cell depletion, no T-depl: no T-cell depletion, 
RIC: reduced intensity conditioning, MC: myeloablative conditioning, AL: acute leukaemia, CML: chronic 
myeloid leukaemia, Lymph: lymphoma, Other Dx: other diagnoses (different than AL, CML, or Lymph), 
≤2000: transplant up to and including 2000, >2000: transplant after 2000. 
 
a P value from the likelihood ratio test: 1. <0.05, 2. [0.05, 0.10], 3. >0.10, - polymorphism was not among the top ten. 
b Top polymorphisms from the whole cohort (Table 3). SNP rs numbers are followed by the minor allele.  
c Haplotype D-IL10 was within the top ten polymorphisms with haplo-genotype (ACC/ACC). This polymorphism appears 
within the top ten list with haplotype GCC in subgroups MUD, AL, and >2000; and with haplotype ATA in subgroups CML 
and Other Dx.  
 
Supplementary Table 2. 
  
P-values for the association of selected polymorphisms with different causes of death 
(n=419), using a Cox regression model including a single polymorphism and the EBMT-score. 
 
Genes from 
 
Patient (P-), 
Donor (D-) 
Polymorphism a 
P-values from LRT b 
Overall 
death 
Cause of death 
Relapse Infection GvHD 
D-IL10 genotype(ACC/ACC) 0.013 0.003 0.503 0.494 
P-MAL rs8177374(T) add. 0.023 0.019 0.568 0.026 
P-ESR1 rs9340799(G) dom. 0.006 0.050 0.086 0.118 
D-IL6 rs1800795(C) add. 0.006 0.100 0.003 0.680 
 
 a Patients (P-) or Donors (D-). For the SNPs listed, the rs number is followed by the minor allele and the respective genetic 
model: additive (add.) or dominant (dom.). 
b P-value for the likelihood ratio test comparing a Cox model including the EBMT-score and the polymorphism with respect 
to a model including  only the EBMT-score. 
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Supplementary Section A 
Biallelic SNPs were evaluated under the additive, dominant and recessive modes of 
inheritance. As an example of coding, consider 3 genotypes AA, AT and TT and T as the 
minor allele: dominant coding is (AT or TT)=1,  AA=0; recessive coding is: TT=1, (AT or AA)=0; 
additive coding is: AA=0, AT=1, TT=2. For the IL-10 haplotype analysis, there are three 
possible haplotypes GCC, ATA and ACC – the haplo-genotypes of IL10 could therefore be 
GCC/GCC; GCC/ATA; GCC/ACC; ATA/ATA; ATA/ACC or ACC/ACC – thus binary coding for 
comparing a particular haplo-genotype to others was, for example, ACC/ACC=1, others=0. 
 
Supplementary Section B 
The EBMT-genetic-score is derived after summing the risk score elements of the EBMT-score 
and genetic factors (final column, Table 4). For example, a patient with EBMT-score=3, 
presence of IL-10 (ACC/ACC) in the donor (contribution 0), presence of TT for MAL (patient) 
(contribution 2), presence of AG or GG for ESR1 (patient) (contribution 2) and presence of 
CC for IL-6 (donor) (contribution 2) would have EBMT-genetic-score= 3+0+2+2+2= 9. 
 
Supplementary Section C 
 
 
 
 
 
where 
 
 
 
 
and 
 
 
 
 
 
 incorporates a bootstrap cross-validation estimator.  In this case, the bootstrapping 
cross-validation procedure is implemented by sampling a data set (of size n) with 
replacement, this data set is a ‘bootstrap sample’ and acts as a training sample to calculate a 
model. The model is then tested on the data not used in the training sample – i.e. these data 
act as a validation set.  The observed and predicted values are compared.  This procedure is 
repeated many times and an average found – this is the ‘bootstrap cross-validation estimate 
of the prediction errors’.  
 
For    and , the predicted values are calculated 
using the Cox model with the indicated factors included; for   the predicted values 
are calculated using a model without factors,(corresponding to the baseline survival risk).  
 
 is small when there is good agreement between observed and predicted values and 
 is large when there is poor agreement between observed and predicted values.  
Therefore a value of 0% for R2 means that the model with EBMT-score and genetic factors 
and the model with EBMT-score alone have equivalent predictive ability; a value of 100% for 
R2 means that the model with EBMT-score and genetic factors has perfect predictive ability 
(i.e. the predicted and observed outcome always agree). 
